About us

about-us
Our history Our team Our partners

Founded in 2009, Fabentech specialises in the development and production of polyclonal antibody treatments for fighting high-priority biological agents which could threaten public health.

Our platform is based on a safe, tested and fully validated polyclonal antibody technology, initially developed by Sanofi Pasteur and enhanced by the Fabentech R&D team for more than a decade. Our Integrated R&D and proprietary manufacturing site enable rapid developments of medical countermeasures against different targets. We are using our expertise to offer reliable protection and treatments ready to face proliferating risks.

Our history

Fabentech has over 14 years of experience in the development and production of emergency care solutions and medical countermeasures.

Fabentech’s key milestones

2009

Inception of the company

2012

Phase I Clinical study of FabenFLU® treatment against H5N1 Avian Influenza infection.

2015

Launch of the Ebola Program in collaboration with the World Health Organisation (WHO) and with the support of the European Medicines Agency (EMA).

Orphan drug status (ODD) in Europe for FabenFLU® treatment against H5N1 Avian Influenza infection.

2017

First collaboration with the French Army on a first antidote against a highly lethal plant-based toxin.

2019

Fabentech raises 8.5 million euros led by Definvest, the Armed forces ministry fund managed by Bpifrance, with participation by Institut Mérieux and its historical investors.

2020

Launch of FabenCOV®, an immunotherapy program to treat Covid-19 infections

Sebastien IVA is appointed CEO of Fabentech

Bio-production: Fabentech presents its new industrial site

2021

Fabentech is awarded 9.2 million euros to develop its FabenCOV® treatment against Covid-19 and its variants in the context of European HERA projects

2022

Launch of a new program to treat Nipah virus infection

The company is granted of 5m€ through the COUNTERACT European consortium to launch several biodefence programs funded by the European Defense Fund.

Our team

Fabentech can count on the skills and energy of an experienced and mobilised team with strong track records in the pharmaceutical industry.

Executive committee

Management team

Supervisory board

  • Philippe Archinard
    Chairman of the supervisory board, Institut Mérieux
  • Franck Lescure
    Auriga Partners, a venture capital management firm
  • Guillaume Hemmerle
    Trail, a venture capital management firm
  • Marielle Mailhes
    BPI France Investissement, Public Bank of Investment
  • Sandra Dubos
    Kreaxi, an investment management firm, specialised in equity financing of innovative startups
  • Bertrand Lépine
    Founder of Fabentech
  • Albert Saporta
    Censor

Fabentech successful team

TEAM

Our partners

From public support to research institutes, Fabentech can count on a network of local, national and international partners to participate in the development of its medical countermeasures.

Investors

Public supports

Research Institutes

Institutions

Download Fabentech presentation

Download